GATA3 and MDM2 are synthetic lethal in estrogen receptor-positive breast cancers
Gaia Bianco, Mairene Coto-Llerena, John Gallon and 23 more
Communications Biology · 2022
doi:10.1038/s42003-022-03296-x (opens in a new tab)
We email you when a new notice or a question about this paper appears.
Abstract
GATA3 mutations are common in ER-positive breast cancers yet are not targetable. This study describes pharmacological inhibition of MDM2 as a novel approach to target GATA3 deficiency, providing a molecularly guided treatment for this patient subclass associated with a worse prognosis and relapse.
Abstract licence: CC BY-NC-ND
Reads
Read by people on this page
None yet.
Checked or read by AI through naulon
None yet.
A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.
Are you an author?
Is this your paper?
Claim it to add your note and be paid when agents cite it. Free.